CytoMed Therapeutics Limited Ordinary Shares (GDTC NASDAQ) stock market data APIs

$2.1725 -0.07(-3.2%)
as of July 1, 2025
Try our APIs with free plan!

CytoMed Therapeutics Limited Ordinary Shares Financial Data Overview

Price chart is built with Anychart

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company also has Business & Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.

Prev. Close 2.1725
Open 2.1067
High 2.2511
Low 2.0804
52 wk Range 1.2-4.0499
Market Cap 25 965 K
Shares Outstanding 11 540 K
Revenue 503 K
Beta -0.314

Why to choose EODHD?

Prices start at $19.99

24/7 Live support

Robust, powerful and reliable data

API Simplicity of a few lines of code


Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW

Get CytoMed Therapeutics Limited Ordinary Shares data using free add-ons & libraries


Get CytoMed Therapeutics Limited Ordinary Shares Fundamental Data

CytoMed Therapeutics Limited Ordinary Shares Fundamental data includes:

  • Net Revenue: 503 K
  • EBITDA: -2 800 818
  • Earnings Per Share:
  • Income Statements
  • Balance Sheets
  • Cash flows

Plans with Fundamental data

Starting from

$ 59.99 /mo.
COMPARE PLANS

End-of-day & Earnings data

Get CytoMed Therapeutics Limited Ordinary Shares Earnings data

Calendar & News package for

$ 19.99 /mo.

What’s included:

  • Latest Release: 2024-12-31
  • EPS/Forecast: -0.04
GET THE PACKAGE

Get CytoMed Therapeutics Limited Ordinary Shares End-of-day data

EOD Historical Data package for

$ 19.99 /mo.

What’s included:

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
GET THE PACKAGE

CytoMed Therapeutics Limited Ordinary Shares News

Get Apple Inc fresh news feed via Financial News API

Calendar & News package for

$19.99/mo.

Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW
  • Flexibility: No long-term commitments, just a minimum of one month
  • Instant access: Get your API key and instructions within seconds of subscribing
  • Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.

What’s included:

  • API Calls per Day: 100 000/day
  • API Requests per Min.: 1000/minute
  • Type of Usage: Personal use

Data access:

Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.

GET THE PACKAGE
Chat